



09/10-02

PHA 4 2.2 (2891/3)  
PATENT

SEARCHED  
INDEXED  
FILED  
TECH CENTER 1600  
OCT 16 2002  
09/10-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of P. Isakson et al.

Art Unit 1627

Serial No. 10/038,080

Filed January 3, 2002

Confirmation No. 7358

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS  
WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A  
LEUKOTRIENE B<sub>4</sub> RECEPTOR ANTAGONIST

Examiner Friend

September 9, 2002

**AMENDMENT B**

TO THE ASSISTANT COMMISSIONER FOR PATENTS,  
Washington, D.C. 20231

SIR:

In response to the Office action mailed August 9, 2002,  
please enter the following amendments:

**IN THE CLAIMS:**

**Please replace Claim 2 with the following:**

2. (twice amended) A combination comprising a therapeutically-effective amount of a leukotriene B<sub>4</sub> receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]), meloxicam (2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide), flosulide (Methanesulfonamide, -[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]), Merck MK-966 (2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl), Merck L-752,860 and compounds of Formula I

